Cervical cancer screening in high-and low-resource countries:Implications and new developments

Obstetrical and Gynecological Survey

Volumn 67, Issue 10, 2012, Pages 658-667

  Hoppenot, Claire ^a   Stampler, Kate ^b   Dunton, Charles ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; WART VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; DEVELOPED COUNTRY; DEVELOPING COUNTRY; FEMALE; HEALTH CENTER; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TESTING; LABORATORY TEST; MIXED INFECTION; PRECANCER; PREDICTIVE VALUE; PRIMARY PREVENTION; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; STAFF TRAINING; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ACETIC ACID; CERVICAL INTRAEPITHELIAL NEOPLASIA; COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; EARLY DETECTION OF CANCER; FEMALE; HIV INFECTIONS; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84869413149     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e3182732375     Document Type: Review

References (44)

1. Campion M. Preinvasive disease. In Berek J, Hacker N, eds. Berek and Hacker's Gynecologic Oncology, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:268-340.
2. Garland SM, Cuzick J, Domingo EJ, et al. Recommendations for cervical cancer prevention in Asia Pacific. ICO Monograph Series on HPV and Cervical Cancer: Asia Pacific Regional Report. Vaccine. 2008;26S:M89YM98.
3. Goldie S, Gaffikin L, Goldhaber-Fiebert J, et al. Costeffectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2005;353:2158-2168.
4. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirusYbased and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;26S:K29YK41.
5. Wright T. Cervical cancer screening in the 21st century: is it time to retire the Pap smear? Clin Obstet Gynecol. 2007;50: 313-325.
6. Gravitt P, Belinson JL, Salmeron J, et al. Looking ahead: a case for human papillomavirus testing of self-sampled vaginal specimens as a cervical cancer screening strategy. Int J Cancer. 2011;129:517-527.
7. Sankaranarayanan R, Rjkumar R, Theresa R, et al. Initial results from a randomized trial of cervical visual screening in rural south India. Int J Cancer. 2004;109:461-467.
8. Kitchener HC, Almonte M, Gilham C, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009;13:1-81.
9. Sankaranarayanan R, Gaffikin L, Jacob M, et al. A critical assessment of screening methods for cervical neoplasia. Int J Gynecol Obstet. 2005;89:S4-S12.
10. Ferreccio C, Barriga MI, Lagos M, et al. Screening trial of human papillomavirus for early detection of cervical cancer in santiago, Chile. Int J Cancer [published online ahead of print June 2012]. Available at: http://onlinelibrary.wiley.com/doi/10.1002/ijc.27662/full. Accessed June 20, 2012. Malden, MA: Wiley Online Library.
11. Arbyn M, Sankaranarayanan R, Muwonge R, et al. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer. 2008;123:153-160.
12. Sangwa-Lugoma G, Mahmud S, Nasr S, et al. Visual inspection as cervical cancer screening in a primary health care setting in Africa. Int J Cancer. 2006;119:1389-1395.
13. Zhao FH, Lin MJ, Chen F, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol. 2010;11:1160-1171.
14. Franceschi S, Jaffe H. Cervical cancer screening of women living with HIV infection; a must in the era of antiretroviral therapy. Clin Infect Dis. 2007;45:510-513.
15. Ditzina LR, David-West G, Maza M, et al. Cervical cancer screening in low-and middle-income countries. Mt Sinai J Med. 2011;78:319-326.
16. Levin CE, Sellors J, Shi JF, et al. Cost-effectiveness analysis of cervical cancer prevention based on rapid human papillomavirus screening test in a high-risk region of China. Int J Cancer. 2010;127:1404-1411.
17. Franceschi S, Cuzick J, Herrero R, et al. EUROGIN 2010 roadmap on cervical cancer prevention. Int J Cancer. 2011;128: 2765-2774.
18. Sankarnarayanan R, Basu P, Wesley RS, et al. Accuracy of visual screening for cervical neoplasia: results from an IARC multicentre study in India and Africa. Int J Cancer. 2004;110: 907-913.
19. Mwanahamuntu M, Shasrabuddhe V, Kapambwe S, et al. Advancing cervical cancer prevention initiatives in resourceconstrained settings: insights from cervical cancer prevention program in Zambia. PloS Med. 8:e1001032. DOI 10.1371/journal.pmed.1001032.
20. Sankaranarayanan R, Esmy PO, Rajkumar R, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet. 2007; 370:398-406.
21. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV Screening for cervical cancer in rural India. N Engl J Med. 2009; 360:14.
22. Mwanahamuntu MH, Sahasrabuddhe VV, Prham GP. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;361:305.
23. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005; 366:991-998.
24. Monsonego J, Hudgens M, Zerat L, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquidbased cytology in primary cervical cancer screening: the FASE study. Int J Cancer. 2011;129:691-701.
25. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249-257.
26. Qiao Y, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a crosssectional study of clinical accuracy in rural China. Lancet Oncol. 2008;9:929-936.
27. Womack S, Chirenje ZM, Gaffikin L, et al. HPV-based cervical cancer screening in a population at high risk for HIV infection. Int J Cancer. 2000;85:206-210.
28. Rijkaart D, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBSCAM randomised controlled trial. Lancet Oncol. 2012;13:78-88.
29. Taylor S, Wang C, Wright T, et al. A comparison of human papillomavirus testing of clinician-collected and self-collected samples during follow-up after screen-and-treat. Int J Cancer. 2010;129:879-886.
30. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, et al. Selfcollection of VAGINAL SPECIMENS for human papillomavirus testing in cervical cancer prevention (MARCH): a communitybased randomised controlled trial. Lancet [published online ahead of print]. Available at: http://www.thelancet.com/journals/lancet/ article/PIIS0140-6736(11)61522-5/fulltext. Accessed November 5, 2011. Amsterdam, the Netherlands: Elsevier Inc.
31. Kotanimei-Talonen L, Nieminen P, Anttila A, et al. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer. 2005;93: 862-867.
32. Denny L, Kuhn L, Hu CC, et al. Human Papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst. 2010;102:1557-1567.
33. Armstrong E. A review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm. 2010;16:217-230.
34. Thiry N, De Laet C, Hustaert F, et al. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening. Int J Technol Assess Health Care. 2009;25:161-170.
35. Bratcher L, Sahasrabuddhe V. The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research. Infect Agents Cancer. 2010;5:8.
36. Maiman M, Fruchter R, Sedlis A, et al. Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Gynecol Oncol. 1998;68:233-239.
37. Sun XW, Kuhn L, Ellerbrock TV, et al. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med. 1997;337:1343-1349.
38. Petry KU, Scheffel D, Bode U, et al. Cellular immunodeficiency enhances the progression of human papillomavirusYassociated cervical lesions. Int J Cancer. 1994;57:836-840.
39. Kuhn L, Wang C, Tsai WY, et al. Efficacy of human papillomavirusYbased screen-and-treat for cervical cancer prevention among HIV infectedwomen. AIDS. 2010;24:2553-2561.
40. Auvert B, Marais D, Lissouba P, et al. High-risk Human Papillomavirus is associated with HIV acquisition among South African female sex workers [published online ahead of print July 3, 2011]. Infect Dis Obstet Gynecol. 2011;692012.
41. Omar T, Shwartz S, Hanrahan C, et al. Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort. AIDS. 2011;25: 87-94.
42. Heard I. Prevention of cervical cancer in women with HIV. Curr Opin HIV AIDS. 2009;4:68-73.
43. Chirenje ZM. HIV and cancer of the cervix. Best Pract Res Clin Obstet Gynaecol. 2005;19:269-276.
44. Mwanahamuntu MH, Sahasrabuddhe VV, Pfaendler KS, et al. Implementation of 'see-and-treat' cervical cancer prevention services linked to HIV care in Zambia. AIDS. 2009;23:N1-N5.